SEC Company Response from Radiopharm Theranostics (RADX) — Dec 19, 2025
Radiopharm Theranostics Ltd
Date: Dec. 19, 2025 · CIK: 0001949257 · Accession: 0001213900-25-123911
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292198
Letter
Re: Radiopharm Theranostics Limited
December 19, 2025
via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Registration Statement on Form F-3
Filed December 17, 2025
File No. 333-292198
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, Radiopharm Theranostics Limited (the "Registrant") respectfully requests acceleration of its Registration Statement on Form F-3 (File No. 333-292198), filed on December 17, 2025, so that it will become effective at 9:00 a.m. (Eastern time) on December 23, 2025, or as soon as practicable thereafter.
If you have any questions, or require any additional information, please do not hesitate to email Andrew Reilly, the Registrant's outside counsel, at andrew.reilly@rimonlaw.com.
The Registrant acknowledges that, if the Securities and Exchange Commission (or its staff, acting pursuant to delegated authority) (the "Commission") declares the filing effective, such action:
(i) does not foreclose the Commission from taking any action with respect to the filing;
(ii) does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
(iii) may not be asserted by the Registrant as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Radiopharm Theranostics Limited
Show Raw Text
CORRESP 1 filename1.htm December 19, 2025 via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Radiopharm Theranostics Limited Registration Statement on Form F-3 Filed December 17, 2025 File No. 333-292198 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, Radiopharm Theranostics Limited (the "Registrant") respectfully requests acceleration of its Registration Statement on Form F-3 (File No. 333-292198), filed on December 17, 2025, so that it will become effective at 9:00 a.m. (Eastern time) on December 23, 2025, or as soon as practicable thereafter. If you have any questions, or require any additional information, please do not hesitate to email Andrew Reilly, the Registrant's outside counsel, at andrew.reilly@rimonlaw.com. The Registrant acknowledges that, if the Securities and Exchange Commission (or its staff, acting pursuant to delegated authority) (the "Commission") declares the filing effective, such action: (i) does not foreclose the Commission from taking any action with respect to the filing; (ii) does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) may not be asserted by the Registrant as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, Radiopharm Theranostics Limited /s/ Riccardo Canevari Riccardo Canevari Chief Executive Officer and Managing Director